Skip to Content
Merck
  • Pioglitazone inhibits angiotensin II-induced atrial fibroblasts proliferation via NF-κB/TGF-β1/TRIF/TRAF6 pathway.

Pioglitazone inhibits angiotensin II-induced atrial fibroblasts proliferation via NF-κB/TGF-β1/TRIF/TRAF6 pathway.

Experimental cell research (2014-08-26)
Xiao-qing Chen, Xu Liu, Quan-xing Wang, Ming-jian Zhang, Meng Guo, Fang Liu, Wei-feng Jiang, Li Zhou
ABSTRACT

The exact mechanisms underlying inhibitory effects of pioglitazone (Pio) on Angiotensin II (AngII)-induced atrial fibrosis are complex and remain largely unknown. In the present study, we examined the effect of Pio on AngII-induced mice atrial fibrosis in vivo and atrial fibroblasts proliferation in vitro. In vivo study showed that AngII infusion induced atrial fibrosis and increased expressions of Toll/IL-1 receptor domain-containing adaptor inducing IFN-β (TRIF) and tumor necrosis factor receptor associated factor 6 (TRAF6) in mice models. However, those effects could be attenuated by Pio (P<0.01). As for in vitro experiment, Pio suppressed AngII-induced atrial fibroblasts proliferation via nuclear factor-κB/transforming growth factor-β1/TRIF/TRAF6 signaling pathway in primary cultured mice atrial fibroblasts (P<0.01). In conclusion, suppression of Pio on AngII-induced atrial fibrosis might be related to its inhibitory effects on above signaling pathway.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Angiotensin II human, ≥93% (HPLC), powder
Pioglitazone for system suitability, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Pioglitazone hydrochloride, ≥98% (HPLC)
USP
Pioglitazone hydrochloride, United States Pharmacopeia (USP) Reference Standard
Pioglitazone hydrochloride, European Pharmacopoeia (EP) Reference Standard